Global Venous Thromboembolism Treatment Market Size, Share, Growth Analysis Report - Forecast 2034

Global Venous Thromboembolism Treatment Market: Industry Perspective

The global venous thromboembolism treatment market size was worth around USD 1.98 Billion in 2024 and is predicted to grow to around USD 4.70 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 8.3% between 2025 and 2034. The report analyzes the global venous thromboembolism treatment market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the venous thromboembolism treatment industry.

Request Free Sample

Global Venous Thromboembolism Treatment Market: Overview

Venous thromboembolism (VTE) is defined as a clot of blood beginning in a vein. It is the third leading vascular disease that affects about 300,000 and 600,000 Americans every year following heart attack and stroke. Operation, cancer, immobilization, and hospitalization are the most common factors that trigger venous thromboembolism. Deep vein thrombosis is observed in the legs when the blood flow slows down or changes are observed in the blood flow. In women, during pregnancy, the use of hormones for menopause symptoms, such as oral contraceptives or estrogen, can also play a vital role in causing venous thromboembolism.  

Global Venous Thromboembolism Treatment Market: Growth Factors

Evidence-based recommendations are available to support healthcare providers in clinical decision-making to treat pulmonary embolism & deep vein thrombosis and this aspect can propel the global venous thromboembolism treatment market growth. Furthermore, escalating demand for cost-effective treatment is also expected to boost the growth of the market globally. Increasing rates of inferior vena cava filters will bolster the global market trends. A surge in heart disorders and an increase in the occurrence of cancer can prompt the demand for venous thromboembolism treatment. Growing awareness among the people about venous thromboembolism treatment will proliferate the size of the global market in the years ahead.

The launching of anticoagulant drugs by pharmaceutical firms is predicted to embellish the global market demand. An increase in the cases of venous thromboembolism can be attributed to an inactive lifestyle, huge alcohol consumption, and intake of a non-nutritive diet and this can pave the way for massive demand for venous thromboembolism treatment. New product launches have always influenced the growth of every sector and the medical sector is no exception to this. For instance, in the first half of 2024, Jansen Pharmaceuticals, Inc., a key pharmaceutical firm based in Belgium, declared that it received approval from the U.S.FDA for its newly launched product referred to as XARELTO® for treating pulmonary embolism and deep venous thrombosis.

Restraints:

Treatment of venous thromboembolism depends on antibiotics that can have side effects on the health of patients. This, in turn, can hamper the growth of the global venous thromboembolism treatment industry expansion.

Opportunities:

The evolution of a slew of mechanical and surgical therapies will open new growth avenues for the global venous thromboembolism treatment market in the upcoming years. A surge in the number of orthopedic surgical operations will help the global market explore new growth spaces in the coming years.

Challenges:

Complications arising after medical treatment and stent placement can prove to be a big challenge for the global industry expansion

Post-procedure complications related to stent placement and low awareness about venous thromboembolism treatment will pose a huge challenge to the global venous thromboembolism treatment industry expansion.

Key Insights

• As per the analysis shared by our research analyst, the global venous thromboembolism treatment market is estimated to grow annually at a CAGR of around 8.3% over the forecast period (2025-2034).
• Regarding revenue, the global venous thromboembolism treatment market size was valued at around USD 1.98 Billion in 2024 and is projected to reach USD 4.70 Billion by 2034.
• The venous thromboembolism treatment market is projected to grow at a significant rate due to growing prevalence of blood clotting disorders, aging population, advancements in anticoagulant therapies, and increasing surgical procedures.
• Based on Product, the Non-Segmented Pneumatic Compression Pumps segment is expected to lead the global market.
• On the basis of Disease Indication, the Deep Venous Thrombosis segment is growing at a high rate and will continue to dominate the global market.
• Based on the End User, the Hospitals segment is projected to swipe the largest market share.
• Based on region, North America is predicted to dominate the global market during the forecast period.

Global Venous Thromboembolism Treatment Market: Report Scope

Global Venous Thromboembolism Treatment Market: Segmentation

Request Free Sample

The global venous thromboembolism treatment market is sectored into product, disease indication, end-user, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2025 to 2034.

In terms of product, global venous thromboembolism treatment market is segregated into upper pneumatic compression sleeves, lower pneumatic compression sleeves, permanent inferior vena cava filters, retrievable inferior vena cava filters, embolectomy balloon catheters, percutaneous thrombectomy devices, catheter-directed thrombolysis (CDT) devices, non-segmented pneumatic compression pumps, segmented pneumatic compression pumps without gradient, and segmented pneumatic compression pumps with calibrated gradient segments.

Furthermore, the retrievable inferior vena cava filters segment, which gained nearly 52% of the global market revenue in 2024, is expected to record the fastest CAGR in the forecasting timeline. The growth of the segment in the forecasting years can be due to the benefits such as health improvement, effectiveness, percutaneous recovery, and protection from pulmonary embolism provided by retrievable inferior vena cava filters to patients.

Based on disease indication, the global venous thromboembolism treatment industry is segmented into deep venous thrombosis and pulmonary embolism segments. During the expected timeframe, the pulmonary embolism segment is projected to observe a massive surge. The segmental surge can be primarily attributed to increased pulmonary embolism prevalence. In addition, various programs are planned to encourage segmental growth to increase public understanding of pulmonary embolism.

Based on end-user, the venous thromboembolism treatment market is segmented into hospitals, ambulatory surgical centers, clinics, and others. The hospital segment is projected to grow exponentially over the analysis period. The segmental expansion can be attributed to an upsurge in the patient population base coupled with increasing vena cava surgical procedures performed by surgeons in hospitals.

The Regional, this segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America,and the Middle East and Africa.

Global Venous Thromboembolism Treatment Market: Regional Insights

The Venous Thromboembolism (VTE) treatment market shows significant regional variation, with North America leading due to a high prevalence of VTE-related conditions, well-established healthcare infrastructure, and strong adoption of advanced anticoagulant therapies. Europe follows closely, supported by rising awareness, aging populations, and increasing focus on early diagnosis and preventive care. The Asia-Pacific region is expected to witness the fastest growth, driven by improving healthcare access, growing patient populations, and expanding government healthcare initiatives in countries like China and India. Meanwhile, Latin America, the Middle East, and Africa are gradually emerging due to increasing healthcare investments and awareness campaigns, though challenges such as limited access to advanced treatment options and affordability persist in these regions.

Global Venous Thromboembolism Treatment Market: Competitive Analysis

The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the venous thromboembolism treatment market on a global and regional basis.

The global venous thromboembolism treatment market is dominated by players like:

• Stryker Corporation
• Argon Medical Devices
• Cardinal Health (Medtronic)
• Cook Medical
• Boston Scientific Corporation
• Koninklijke Philips N.V.
• Arjo
• DJO Global

Global Venous Thromboembolism Treatment Market: Segmentation Analysis

The global venous thromboembolism treatment market is segmented as follows;

By Product

• Non-Segmented Pneumatic Compression Pumps
• Segmented Pneumatic Compression Pumps without Gradient
• Segmented Pneumatic Compression Pumps with Calibrated Gradient
• Upper Pneumatic Compression Sleeves
• Lower Pneumatic Compres

By Disease Indication

• Deep Venous Thrombosis
• Pulmonary Embolism

By End User

• Hospitals
• Catheterisation Laboratories
• Ambulatory Surgical Centres

Global Venous Thromboembolism Treatment Market: Regional Segment Analysis

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America